A team of researchers from the University of Michigan Department of Pathology has identified a previously unknown vulnerability in one of the most aggressive forms of pediatric brain cancer, opening the door to potential new treatment strategies for children with limited therapeutic options.
Effective September 30, 2026, the 1p/19q Deletion by FISH assay will be discontinued. To assess for 1p/19q co-deletion, laboratories should order Cytogenetics, Chromosomal Microarray Analysis, FFPE Tissue (order code: CGAPT).
Anew University of Michigan initiative aims to address one of biomedical research’s most persistent challenges: why therapies that succeed in animal models often fail in human patients. Now, a new initiative led by Drs. Simon P. Hogan, the Askwith Research Professor of Food Allergy, Mary H. Weiser Food Allergy Center and Professor of Pathology, and Nicholas W. Lukacs, the Godfrey Dorr Stobbe Professor of Pathology and interim Director of the Mary H. Weiser Food Allergy Center, aims to help close that gap.
Dr. Maria Westerhoff, alongside Co-Lead Author Dr. Sanjay Kakar of the University of California, San Francisco, has captured the latest advancements in gastrointestinal pathology in the newly published fourth edition of Diagnostic Pathology: Hepatobiliary and Pancreas. Published by Elsevier, the full-color textbook is now available as a comprehensive, expertly curated guide to one of the most challenging areas in pathology.
Researchers at the University of Michigan have identified a previously unrecognized survival mechanism in neuroendocrine prostate cancer (NEPC), one of the most aggressive and difficult-to-treat forms of prostate cancer. The findings, which have been published in Cancer Cell, uncover a critical vulnerability in NEPC and suggest a novel dual-targeting strategy that could eventually lead to more effective treatment options for patients with advanced disease.
Less than two years after arriving at the University of Michigan, physician-scientist Navin Rajput Mahadevan, MD, PhD, has been named a Taubman Emerging Scholar, receiving five years of support to advance research aimed at improving outcomes for patients with small cell lung cancer, one of the deadliest forms of cancer.
U-M neuropathologist Sriram Venneti, MD, PhD, was recently featured in The New York Times for his research on diffuse midline glioma (DMG), one of the deadliest pediatric brain cancers. The national feature highlights how his work has helped transform scientists' understanding of the disease and paved the way for new treatment options that are offering hope to children and families worldwide.
After a distinguished career spanning nearly four decades in laboratory medicine, Karla S. Bialk, MS, MT (ASCP), business development strategist at Michigan Medicine, is retiring, leaving behind a legacy of leadership, innovation, and mentorship.
The Michigan Department of Health and Human Services (MDHHS) and local health departments are investigating a recent increase in cyclosporiasis cases, primarily affecting Southeast Michigan counties along the Ohio border. Cyclosporiasis cases typically increase during the summer months; however, the current increase is above expected seasonal incidence. Investigations are underway to identify a potential common exposure or source.
By Lynn McCain When Dr. David Manthei talks about his work, one theme comes up again and again: connection. Whether he is bringing together laboratory teams, mentoring residents, or collaborating with clinicians across disciplines, his focus is on strengthening relationships that ultimately improve patient care. Named Associate Director of the Clinical Pathology Division on March 1, 2026, Manthei brings a broad perspective shaped by his many roles. He serves as Section Director of Immunology and Special Chemistry, Associate Program Director for the Pathology Residency Program, Program Director